Quadrant Capital Group’s Passage Bio PASG Stock Holding History

Quadrant Capital Group’s Portfolio PASG Stock Details PASG Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2021 Q4	–	Sell	-9	Closed	-$2K	–	2649
2021 Q3	$2K	Buy	+9	New	+$2.15K	﹤0.01%	2170

Other funds holding PASG

OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return

Frazier Management Seattle, Washington $1.12M AUM 151.58% 1-Year Est. Return

VVM

Versant Venture Management San Francisco, California $141M AUM 190.82% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

DTC

Deep Track Capital Greenwich, Connecticut $6.12B AUM 144% 1-Year Est. Return

NLVP

New Leaf Venture Partners New York $43M AUM 25.55% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Woodline Partners San Francisco, California $26.4B AUM 44.85% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Quadrant Capital Group's PASG Position: Q4 2021 in Review

Quadrant Capital Group sold out of Passage Bio (PASG) in Q4 2021, closing a stake of 9 shares — an estimated $2K sold.

Quadrant Capital Group first reported a position in PASG in Q3 2021 and held it in 1 quarter. The position peaked at $2K in Q3 2021. 99 funds tracked by Wall St. Rank hold PASG as of Q4 2021.

Quadrant Capital Group reported no remaining Passage Bio position as of Q4 2021 after selling out during the quarter.
Quadrant Capital Group sold 9 Passage Bio shares in Q4 2021, an estimated $2K.
Quadrant Capital Group first reported a position in Passage Bio in Q3 2021 and held it in 1 quarter.
Quadrant Capital Group's Passage Bio position peaked at $2K in Q3 2021.
99 funds tracked by Wall St. Rank held Passage Bio as of Q4 2021.

Based on Quadrant Capital Group's 13F filing for Q4 2021, filed 1 Feb 2022.